The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Mar. 11, 2015
Applicant:

Phadia Ab, Uppsala, SE;

Inventor:

Henrik Grönberg, Stockholm, SE;

Assignee:

PHADIA AB, Uppsala, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); G06F 19/00 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57434 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57473 (2013.01); G01N 33/57484 (2013.01); G06F 19/34 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/52 (2013.01); G01N 2333/96455 (2013.01);
Abstract

A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%, of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.


Find Patent Forward Citations

Loading…